From the Neuroendocrine Tumors Service, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 52621 (A.T.); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (A.T.); Division of Cancer Epidemiology and Genetics (N.J., C. Lee, A.B.d.G.), Department of Radiology and Imaging Sciences (L.R.F., J.Y., W.K., A.M.), and Urologic Oncology Branch (C. Leite, W.M.L.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Villejuif, France (N.J.); and Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, Calif (E.K.).
Radiology. 2019 Jan;290(1):116-124. doi: 10.1148/radiol.2018180687. Epub 2018 Oct 9.
Purpose To assess the potential ionizing radiation exposure from CT scans for both screening and surveillance of patients with von Hippel-Lindau (VHL) syndrome. Materials and Methods For this retrospective study, abdomen-pelvic (AP) and chest-abdomen-pelvic (CAP) CT scans were performed with either a three-phase (n = 1242) or a dual-energy virtual noncontrast protocol (VNC; n = 149) in 747 patients with VHL syndrome in the National Institutes of Health Clinical Center between 2009 and 2015 (mean age, 47.6 years ± 14.6 [standard deviation]; age range, 12-83 years; 320 women [42.8%]). CT scanning parameters for patients with pancreatic neuroendocrine tumors (PNETs; 124 patients and 381 scans) were compared between a tumor diameter-based surveillance protocol and a VHL genotype and tumor diameter-based algorithm (a tailored algorithm) developed by three VHL clinicians. Organ and lifetime radiation doses were estimated by two radiologists and five radiation scientists. Cumulative radiation doses were compared between the PNET surveillance algorithms by analyses of variance, and a two-tailed P value less than .05 indicated statistical significance. Results Median cumulative colon doses for annual CAP and AP CT scans from age 15 to 40 years ranged from 0.34 Gy (5th-95th percentiles, 0.18-0.75; dual-energy VNC CT) to 0.89 Gy (5th-95th percentiles, 0.42-1.0; three-phase CT). For the current PNET surveillance protocol, the cumulative effective radiation dose from age 40 to 65 years was 682 mSv (tumors < 1.2 cm) and 2125 mSv (tumors > 3 cm). The tailored algorithm could halve these doses for patients with initial tumor diameter less than 1.2 cm (P < .001). Conclusion CT screening of patients with von Hippel-Lindau syndrome can lead to substantial radiation exposures, even with dual-energy virtual noncontrast CT. A genome and tumor diameter-based algorithm for pancreatic neuroendocrine tumor surveillance may potentially reduce lifetime radiation exposure. © RSNA, 2018 Online supplemental material is available for this article.
目的 评估 CT 扫描在希佩尔-林道综合征(VHL)患者筛查和监测中的潜在电离辐射暴露。
材料与方法 本回顾性研究纳入了 2009 年至 2015 年期间在国立卫生研究院临床中心接受 CT 扫描的 747 例 VHL 综合征患者,包括腹部-骨盆(AP)和胸部-腹部-骨盆(CAP)CT 扫描(n=1242 例),以及使用双能虚拟非对比(VNC)协议的 CT 扫描(n=149 例)(平均年龄 47.6 岁±14.6[标准差];年龄范围 12-83 岁;320 例女性[42.8%])。对 124 例患者(381 次扫描)的胰腺神经内分泌肿瘤(PNET)的 CT 扫描参数进行比较,比较了一种基于肿瘤直径的监测方案和由三位 VHL 临床医生开发的基于 VHL 基因型和肿瘤直径的算法(定制算法)。两位放射科医生和五位放射科科学家估计了器官和终身辐射剂量。通过方差分析比较了 PNET 监测算法之间的累积辐射剂量,双侧 P 值小于 0.05 表示具有统计学意义。
结果 年龄 15-40 岁时,每年 CAP 和 AP CT 扫描的结肠累积剂量中位数范围为 0.34 Gy(5 百分位至 95 百分位,0.18-0.75;双能 VNC CT)至 0.89 Gy(5 百分位至 95 百分位,0.42-1.0;三相 CT)。对于当前的 PNET 监测方案,40-65 岁时的有效辐射剂量累积量为 682 mSv(肿瘤<1.2 cm)和 2125 mSv(肿瘤>3 cm)。对于初始肿瘤直径小于 1.2 cm 的患者,定制算法可将这些剂量减半(P<0.001)。
结论 即使使用双能虚拟非对比 CT,VHL 综合征患者的 CT 筛查也会导致大量的辐射暴露。基于基因组和肿瘤直径的胰腺神经内分泌肿瘤监测算法可能会降低终身辐射暴露。
© RSNA,2018
在线补充材料可在本文中获取。